Table 2.
Final results of -2548 G/A LEP and Q223R LEPR polymorphisms in the two groups of patients and controls with the risk of breast cancer.
| Genotypes | Controls n = 41 (%) |
Patients n = 45 (%) |
Odds ratio | 95% confidence interval | p value |
|---|---|---|---|---|---|
| LEP (-2548) G/A | |||||
| GG | 5 (12.2) | 7 (15.6)∗ | 1 | ||
| GA | 19 (46.3) | 11 (24.4) | 0.41 | (0.1–1.62) | 0.2 |
| AA | 17 (41.5) | 27 (60) | 1.13 | (0.3–4.15) | 0.8 |
|
| |||||
| Alleles | |||||
| G-allele | 29 (35.4) | 25 (27.8) | |||
| A-allele | 53 (64.6) | 65 (72.2) | 1.35 | (0.74–2.44) | 0.33 |
|
| |||||
| LEPR Q223R | |||||
| 17 (41.5) | 19 (42.2) | 1∗ | |||
| QR | 18 (43.9) | 25 (55.6) | 8.3 | (0.92–75.36) | 0.06 |
| RR | 6 (14.6) | 1 (2.2) | 6.7 | (0.73–61.5) | 0.09 |
|
| |||||
| Alleles | |||||
| Q-allele | 52 (63.4) | 63 (70) | |||
| R-allele | 30 (36.3) | 27 (30) | 0.71 | (0.36–1.41) | 0.33 |
∗Reference group.